July 25, 2019
Astellas Pharma said on July 24 that the European Medicines Agency (EMA) has accepted its application seeking to expand the use of Xtandi (enzalutamide) to metastatic hormone-sensitive prostate cancer (mHSPC). The filing is based on data from two global PIII...read more